Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias

Disease Markers

Volumn 21, Issue 3, 2005, Pages 105-120

  Goebel, Georg ^a   Zitt, Marion ^a   Zitt, Matthias ^a   Müller, Hannes M ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cell free mRNA; Circulating nucleic acids in plasma or serum; CNAPS; Genetic alterations; Methylated DNA; Microsatellites; Mitochondrial DNA; Monitoring; Neoplasia; Nucleosomes; Plasma; Prognosis; Serum; Viral DNA

Indexed keywords

CIRCULATING NUCLEIC ACIDS IN PLASMA OR SERUM; DNA; MESSENGER RNA; MICROSATELLITE DNA; TUMOR MARKER; UNCLASSIFIED DRUG; VIRUS DNA;

BLOOD FLOW; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL FREE SYSTEM; DISEASE MARKER; DNA METHYLATION; EPSTEIN BARR VIRUS; FOLLOW UP; GENETIC DISORDER; HEPATITIS B VIRUS; HUMAN; NUCLEOSOME; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR;

HEPATITIS B VIRUS; HUMAN HERPESVIRUS 4;

EID: 27644597171     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/218759     Document Type: Review

References (112)

1. P. Mandel and P. Métais, Les acides nucléiques du plasma sanguin chez l'Homme, CR Acad Sci Paris 142 (1948), 241-243.
2. E.M. Tan, P.H. Schur, R.I. Carr and H.G. Kunkel, Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus, J Clin Invest 45 (1966), 1732-1740.
3. S.A. Leon, B. Shapiro, D.M. Sklaroff and M.J. Yaros, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res 37 (1977), 646-650.
4. B. Shapiro, M. Chakrabarty, E.M. Cohn and S.A. Leon, Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease, Cancer 51 (1983), 2116-2120.
5. M. Stroun, P. Anker, P. Maurice, J. Lyautey, C. Lederrey and M. Beljanski, Neoplastic characteristics of the DNA found in the plasma of cancer patients, Oncology 46 (1989), 318-322.
6. G.D. Sorenson, D.M. Pribish, F.H. Valone, V.A. Memoli, D.J. Bzik and S.L. Yao, Soluble normal and mutated DNA sequences from single-copy genes in human blood, Cancer Epidemiol Biomarkers Prev 3 (1994), 67-71.
7. V. Vasioukhin, P. Anker, P. Maurice, J. Lyautey, C. Lederrey and M. Stroun, Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia, Br J Haematol 86 (1994), 774-779.
8. S. Jahr, H. Hentze, S. Englisch, D. Hardt, F.O. Fackelmayer, R.D. Hesch and R. Knippers, DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells, Cancer Res 61 (2001), 1659-1665.
9. G. Sozzi, D. Conte, L. Mariani, V.S. Lo, L. Roz, C. Lombardo, M.A. Pierotti and L. Tavecchio, Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients, Cancer Res 61 (2001), 4675-4678.
10. X. Chen, H. Bonnefoi, S. Diebold-Berger, J. Lyautey, C. Lederrey, E. Faltin-Traub, M. Stroun and P. Anker, Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer, Clin Cancer Res 5 (1999), 2297-2303.
11. Y.Y. Lui, K.W. Chik, R.W. Chiu, C.Y. Ho, C.W. Lam and Y.M. Lo, Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation, Clin Chem 48 (2002), 421-427.
12. T.H. Lee, L. Montalvo, V. Chrebtow and M.P. Busch, Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma, Transfusion 41 (2001), 276-282.
13. P.J. Johnson and Y.M. Lo, Plasma nucleic acids in the diagnosis and management of malignant disease, Clin Chem 48 (2002), 1186-1193.
14. A. Ziegler, U. Zangemeister-Wittke and R.A. Stahel, Circulating DNA: a new diagnostic gold mine?, Cancer Treat Rev 28 (2002), 255-271.
15. T. Minamoto, N. Yamashita, A. Ochiai, M. Mai, T. Sugimura, Z. Ronai and H. Esumi, Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis, Cancer 75 (1995), 1520-1526.
16. G.D. Sorenson, Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer, Clin Cancer Res 6 (2000), 2129-2137.
17. G.D. Sorenson, A review of studies on the detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer, Ann N Y Acad Sci 906 (2000), 13-16.
18. G.D. Kirk, A.M. Camus-Randon, M. Mendy, J.J. Goedert, P. Merle, C. Trepo, C. Brechot, P. Hainaut and R. Montesano, Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia, J Natl Cancer Inst 92 (2000), 148-153.
19. P.E. Jackson, G.S. Qian, M.D. Friesen, Y.R. Zhu, P. Lu, J.B. Wang, Y. Wu, T.W. Kensler, B. Vogelstein and J.D. Groopman, Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry, Cancer Res 61 (2001), 33-35.
20. Z.M. Shao, J. Wu, Z.Z. Shen and M. Nguyen, p53 mutation in plasma DNA and its prognostic value in breast cancer patients, Clin Cancer Res 7 (2001), 2222-2227.
21. J.M. Silva, R. Gonzalez, G. Dominguez, J.M. Garcia, P. Espana and F. Bonilla, TP53 gene mutations in plasma DNA of cancer patients, Genes Chromosomes Cancer 24 (1999), 160-161.
22. F. Mayall, G. Jacobson, R. Wilkins and B. Chang, Mutations of p53 gene can be detected in the plasma of patients with large bowel carcinoma, J Clin Pathol 51 (1998), 611-613.
23. C.D. Gocke, F.A. Benko, M.S. Kopreski and T.J. McGarrity, p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas, Ann N Y Acad Sci 906 (2000), 44-50.
24. J.M. Silva, G. Dominguez, J.M. Garcia, R. Gonzalez, M.J. Villanueva, F. Navarro, M. Provencio, S. San Martin, P. Espana and F. Bonilla, Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations, Cancer Res 59 (1999), 3251-3256.
25. J.M. Silva, J.M. Garcia, G. Dominguez, J. Silva, C. Miralles, B. Cantos, S. Coca, M. Provencio, P. Espana and F. Bonilla, Persistence of tumor DNA in plasma of breast cancer patients after mastectomy, Ann Surg Oncol 9 (2002), 71-76.
26. K. Hibi, C.R. Robinson, S. Booker, L. Wu, S.R. Hamilton, D. Sidransky and J. Jen, Molecular detection of genetic alterations in the serum of colorectal cancer patients, Cancer Res 58 (1998), 1405-1407.
27. R. Dahse, M. Utting, W. Werner, B. Schimmel, U. Claussen and K. Junker, TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples, Int J Oncol 20 (2002), 107-115.
28. F. Coulet, H. Blons, A. Cabelguenne, T. Lecomte, O. Lacourreye, D. Brasnu, P. Beaune, J. Zucman and P. Laurent-Puig, Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis, Cancer Res 60 (2000), 707-711.
29. E. Ling, A. Fich, S. Man, M. Wolfson, R. Mikhailowsky and S.A. Lamprecht, Detection of tumor mutant APC DNA in plasma of patients with sporadic colorectal cancer, In Vivo 14 (2000), 543-546.
30. P.W Chiang, D.G. Beer, W.L. Wei, M.B. Orringer and D.M. Kurnit, Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients, Clin Cancer Res 5 (1999), 1381-1386.
31. N. Bruhn, T. Beinert, C. Oehm, B. Jandrig, I. Petersen, X.Q. Chen, K. Possinger and M. Fleischhacker, Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer, Ann N Y Acad Sci 906 (2000), 72-82.
32. X.Q. Chen, M. Stroun, J.L. Magnenat, L.P. Nicod, A.M. Kurt, J. Lyautey, C. Lederrey and P. Anker, Microsatellite alterations in plasma DNA of small cell lung cancer patients, Nat Med 2 (1996), 1033-1035.
33. R. Gonzalez, J.M. Silva, A. Sanchez, G. Dominguez, J.M. Garcia, X.Q. Chen, M. Stroun, M. Provencio, P. Espana, P. Anker and F. Bonilla, Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance, Ann Oncol 11 (2000), 1097-1104.
34. H. Nawroz, W. Koch, P. Anker, M. Stroun and D. Sidransky, Microsatellite alterations in serum DNA of head and neck cancer patients, Nat Med 2 (1996), 1035-1037.
35. B. Taback, A.E. Giuliano, N.M. Hansen and D.S. Hoon, Microsatellite alterations detected in the serum of early stage breast cancer patients, Ann N Y Acad Sci 945 (2001), 22-30.
36. B. Taback, S.J. O'Day, P.D. Boasberg, S. Shu, P. Fournier, R. Elashoff, H.J. Wang and D.S. Hoon, Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma, J Natl Cancer Inst 96 (2004), 152-156.
37. B. Taback, Y. Fujiwara, H.J. Wang, L.J. Foshag, D.L. Morton and D.S. Hoon, Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients, Cancer Res 61 (2001), 5723-5726.
38. C. Goessl, R. Heicappell, R. Munker, P. Anker, M. Stroun, H. Krause, M. Muller and K. Miller, Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma, Cancer Res 58 (1998), 4728-4732.
39. P.A. Jones and S.B. Baylin, The fundamental role of epigenetic events in cancer, Nat Rev Genet 3 (2002), 415-428.
40. P.W. Laird, Early detection: The power and the promise of DNA methylation markers, Nat Rev Cancer 3 (2003), 253-266.
41. J.G. Herman and S.B. Baylin, Gene silencing in cancer in association with promoter hypermethylation, N. Engl. J. Med. 349 (2003), 2042-2054.
42. H.M. Muller and M. Widschwendter, Methylated DNA as a possible screening marker for neoplastic disease in several body fluids, Expert Rev Mol Diagn 3 (2003), 443-458.
43. Y.M. Lo, L.Y. Chan, A.T. Chan, S.F. Leung, K.W. Lo, J. Zhang, J.C. Lee, N.M. Hjelm, P.J. Johnson and D.P. Huang, Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma, Cancer Res 59 (1999), 5452-5455.
44. Y.M. Lo, L.Y. Chan, K.W. Lo, S.F. Leung, J. Zhang, A.T. Chan, J.C. Lee, N.M. Hjelm, P.J. Johnson and D.P. Huang, Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma, Cancer Res 59 (1999), 1188-1191.
45. Y.M. Lo, A.T. Chan, L.Y. Chan, S.F. Leung, C.W. Lam, D.P. Huang and P.J. Johnson, Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA, Cancer Res 60 (2000), 6878-6881.
46. A. Gallagher, A.A. Armstrong, J. MacKenzie, L. Shield, G. Khan, A. Lake, S. Proctor, P. Taylor, G.B. Clements and R.F. Jarrett, Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease, Int J Cancer 84 (1999), 442-448.
47. H.J. Wagner, F. Schlager, A. Claviez and P Bucsky, Detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction, Eur J Cancer 37 (2001), 1853-1857.
48. K.I. Lei, L.Y. Chan, W.Y. Chan, P.J. Johnson and Y.M. Lo, Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies, Br J Haematol 111 (2000), 239-246.
49. K.I. Lei, L.Y. Chan, W.Y. Chan, P.J. Johnson and Y.M. Lo, Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma, Clin Cancer Res 8 (2002), 29-34.
50. S.M. Dong, S.I. Pai, S.H. Rha, A. Hildesheim, R.J. Kurman, P.E. Schwartz, R. Mortel, L. McGowan, M.D. Greenberg, W.A. Barnes and D. Sidransky, Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma, Cancer Epidemiol Biomarkers Prev 11 (2002), 3-6.
51. R.B. Capone, S.I. Pai, W.M. Koch, M.L. Gillison, H.N. Danish, W.H. Westra, R. Daniel, K.V. Shah and D. Sidransky, Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma, Clin Cancer Res 6 (2000), 4171-4175.
52. W. Pornthanakasem, K. Shotelersuk, W. Termrungruanglert, N. Voravud, S. Niruthisard and A. Mutirangura, Human papillomavirus DNA in plasma of patients with cervical cancer, BMC Cancer 1 (2001), 2.
53. V.W. Liu, P. Tsang, A. Yip, T.Y. Ng, L.C. Wong and H.Y. Ngan, Low incidence of HPV DNA in sera of pretreatment cervical cancer patients, Gynecol Oncol 82 (2001), 269-272.
54. A. Widschwendter, A. Blassnig, A. Wiedemair, E. Muller-Holzner, H.M. Muller and C. Marth, Human papillomavirus DNA in sera of cervical cancer patients as tumor marker, Cancer Lett 202 (2003), 231-239.
55. K. Kuroi, C. Tanaka and M. Toi, Plasma Nucleosome Levels in Node-Negative Breast Cancer Patients, Breast Cancer 6 (1999), 361-364.
56. S. Holdenrieder, P. Stieber, J. Von Pawel, H. Raith, D. Nagel, K. Feldmann and D. Seidel, Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer, Clin Cancer Res 10 (2004), 5981-5987.
57. K. Polyak, Y. Li, H. Zhu, C. Lengauer, J.K. Willson, S.D. Markowitz, M.A. Trush, K.W. Kinzler and B. Vogelstein, Somatic mutations of the mitochondrial genome in human colorectal tumours, Nat Genet 20 (1998), 291-293.
58. C. Jeronimo, S. Nomoto, O.L. Caballero, H. Usadel, R. Henrique, G. Varzim, J. Oliveira, C. Lopes, M.S. Fliss and D. Sidransky, Mitochondrial mutations in early stage prostate cancer and body fluids, Oncogene 20 (2001), 5195-5198.
59. S. Nomoto, K. Yamashita, K. Koshikawa, A. Nakao and D. Sidransky, Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma, Clin Cancer Res 8 (2002), 481-487.
60. O. Okochi, K. Hibi, T. Uemura, S. Inoue, S. Takeda, T. Kaneko and A. Nakao, Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients, Clin Cancer Res 8 (2002), 2875-2878.
61. K. Hibi, H. Nakayama, T. Yamazaki, T. Takase, M. Taguchi, Y. Kasai, K. Ito, S. Akiyama and A. Nakao, Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients, Int J Cancer 94 (2001), 429-431.
62. M.S. Kopreski, F.A. Benko, L.W. Kwak and C.D. Gocke, Detection of tumor messenger RNA in the serum of patients with malignant melanoma, Clin Cancer Res 5 (1999), 1961-1965.
63. D.O. Hasselmann, G. Rappl, M. Rossler, S. Ugurel, W. Tilgen and U. Reinhold, Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma, Oncol Rep 8 (2001), 115-118.
64. X.Q. Chen, H. Bonnefoi, M.F. Pelte, J. Lyautey, C. Lederrey, S. Movarekhi, P. Schaeffer, H.E. Mulcahy, P. Meyer, M. Stroun and P. Anker, Telomerase RNA as a detection marker in the serum of breast cancer patients, Clin Cancer Res 6 (2000), 3823-3826.
65. S.M. Lledo, E. Garcia-Granero, F. Dasi, R. Ripoli, S.A. Garcia, A. Cervantes and S.F. Alino, Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer, Colorectal Dis 6 (2004), 236-242.
66. F. Dasi, S. Lledo, E. Garcia-Granero, R. Ripoll, M. Marugan, M. Tormo, J. Garcia-Conde and S.F. Alino, Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest 81 (2001), 767-769.
67. P. Anker, H. Mulcahy, X.Q. Chen and M. Stroun, Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients, Cancer Metastasis Rev 18 (1999), 65-73.
68. J.P. Issa, N. Ahuja, M. Toyota, M.P. Bronner and T.A. Brentnail, Accelerated age-related cpg island methylation in ulcerative colitis, Cancer Res 61 (2001), 3573-3577.
69. H. Nakagawa, G.J. Nuovo, E.E. Zervos, E.W. Martin, Jr., R. Salovaara, L.A. Aaltonen and C.A. de la, Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite- unstable colorectal cancer development, Cancer Res 61 (2001), 6991-6995.
70. T. Habuchi, T. Takahashi, H. Kakinuma, L. Wang, N. Tsuchiya, S. Satoh, T. Akao, K. Sato, O. Ogawa, M.A. Knowles and T. Kato, Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer, Oncogene 20 (2001), 531-537.
71. D. Garcia-Olmo, D.C. Garcia-Olmo, J. Ontanon, E. Martinez and M. Vallejo, Tumor DNA circulating in the plasma might play arole in metastasis. The hypothesis of the genometastasis, Histol Histopathol 14 (1999), 1159-1164.
72. X. Yao, J.F. Hu, M. Daniels, H. Shiran, X. Zhou, H. Yan, H. Lu, Z. Zeng, Q. Wang, T. Li and A.R. Hoffman, A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma, J Clin Invest 111 (2003), 265-273.
73. D. Garcia-Olmo and D.C. Garcia-Olmo, Functionality of circulating DNA: the hypothesis of genometastasis, Ann N Y Acad Sci 945 (2001), 265-275.
74. A. Bergsmedh, A. Szeles, M. Henriksson, A. Bratt, M.J. Folkman, A.L. Spetz and L. Holmgren, Horizontal transfer of onco-genes by uptake of apoptotic bodies, Proc Natl Acad Sci USA 98 (2001), 6407-6411.
75. H.M. Muller, A. Widschwendter, H. Fiegl, L. Ivarsson, G. Goebel, E. Perkmann, C. Marth and M. Widschwendter, DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63 (2003), 7641-7645.
76. C.A. Klein, T.J. Blankenstein, O. Schmidt-Kittler, M. Petronio, B. Polzer, N.H. Stoecklein and G. Riethmuller, Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer, Lancet 360 (2002), 683-689.
77. H.M. Muller, H. Fiegl, A. Widschwendter and M. Widschwendter, Prognostic DNA Methylation Marker in Serum of Cancer Patients, Ann N Y Acad Sci 1022 (2004), 44-49.
78. A. Widschwendter, L. Ivarsson, A. Blassnig, H.M. Muller, H. Fiegl, A. Wiedemair, E. Muller-Holzner, G. Goebel, C. Marth and M. Widschwendter, CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients, Int J Cancer 109 (2004), 163-166.
79. A. Widschwendter, H.M. Muller, H. Fiegl, L. Ivarsson, A. Wiedemair, E. Muller-Holzner, G. Goebel, C. Marth and M. Widschwendter, DNA methylation in serum and tumors of cervical cancer patients, Clin Cancer Res 10 (2004), 565-571.
80. D.F. Hayes, C. Isaacs and V. Stearns, Prognostic factors in breast cancer: current and new predictors of metastasis, J Mammary Gland Biol Neoplasia 6 (2001), 375-392.
81. D.F. Hayes, B. Trock and A.L. Harris, Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?, Breast Cancer Res Treat 52 (1998), 305-319.
82. C. Goessl, Diagnostic potential of circulating nucleic acids for oncology, Expert Rev Mol Diagn 3 (2003), 431-442.
83. T. Yamada, S. Nakamori, H. Ohzato, S. Oshima, T. Aoki, N. Higaki, K. Sugimoto, K. Akagi, Y. Fujiwara, I. Nishisho, M. Sakon, M. Gotoh and M. Monden, Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features, Clin Cancer Res 4 (1998), 1527-1532.
84. A. Castells, P. Puig, J. Mora, J. Boadas, L. Boix, E. Urgell, M. Sole, G. Capella, F. Lluis, L. Fernandez-Cruz, S. Navarro and A. Farre, K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance, J Clin Oncol 17 (1999), 578-584.
85. J.L. Ramirez, C. Sarries, P.L. de Castro, B. Roig, C. Queralt, D. Escuin, A. de, I, J.M. Sanchez, J.L. Manzano, M. Margeli, J.J. Sanchez, J. Astudillo, M. Taron and R. Rosell, Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients, Cancer Lett 193 (2003), 207-216.
86. T. Lecomte, A. Berger, F. Zinzindohoue, S. Micard, B. Landi, H. Blons, P. Beaune, P.H. Cugnenc and P. Laurent-Puig, Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis, Int J Cancer 100 (2002), 542-548.
87. J.M. Silva, J. Silva, A. Sanchez, J.M. Garcia, G. Dominguez, M. Provencio, L. Sanfrutos, E. Jareno, A. Colas, P. Espana and F. Bonilla, Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival, Clin Cancer Res 8 (2002), 3761-3766.
88. Y. Fujiwara, D.D. Chi, H. Wang, P. Keleman, D.L. Morton, R. Turner and D.S. Hoon, Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients, Cancer Res 59 (1999), 1567-1571.
89. C.F. Eisenberger, M. Schoenberg, C. Enger, S. Hortopan, S. Shah, N.H. Chow, F.F. Marshall and D. Sidransky, Diagnosis of renal cancer by molecular urinalysis, J Natl Cancer Inst 91 (1999), 2028-2032.
90. M.L. Gonzalgo, C.F. Eisenberger, S.M. Lee, B.J. Trock, F.F. Marshall, S. Hortopan, D. Sidransky and M.P. Schoenberg, Prognostic significance of preoperative molecular serum analysis in renal cancer, Clin Cancer Res 8 (2002), 1878-1881.
91. G. Dominguez, J. Carballido, J. Silva, J.M. Silva, J.M. Garcia, J. Menendez, M. Provencio, P. Espana and F. Bonilla, p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients, Clin Cancer Res 8 (2002), 980-985.
92. A. Fujimoto, H. Takeuchi, B. Taback, B.C. Hsueh, D. Elashoff, D.L. Morton and D.S. Hoon, Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma, Cancer Res 64 (2004), 2245-2250.
93. A. Fujimoto, S.J. O'Day, B. Taback, D. Elashoff and D.S. Hoon, Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome, Cancer Res 64 (2004), 4085-4088.
94. K. Kawakami, J. Brabender, R.V. Lord, S. Groshen, B.D. Greenwald, M.J. Krasna, J. Yin, A.S. Fleisher, J.M. Abraham, D.G. Beer, D. Sidransky, H.T. Huss, T.R. DeMeester, C. Eads, P.W. Laird, D.H. Ilson, D.P. Kelsen, D. Harpole, M.B. Moore, K.D. Danenberg, P.V. Danenberg and S.J. Meltzer, Hypermethylated ARC DNA in plasma and prognosis of patients with esophageal adenocarcinoma, J Natl Cancer Inst 92 (2000), 1805-1811.
95. H.Z. Zou, B.M. Yu, Z.W. Wang, J.Y. Sun, H. Cang, F. Gao, D.H. Li, R. Zhao, G.G. Feng and J. Yi, Detection of aberrant p16 methylation in the serum of colorectal cancer patients, Clin Cancer Res 8 (2002), 188-191.
96. C.S. Ng, J. Zhang, S. Wan, T.W. Lee, A.A. Arifi, T. Mok, D.Y. Lo and A.P. Yim, Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer, J Surg Oncol 79 (2002), 101-106.
97. J.M. Silva, G. Dominguez, M.J. Villanueva, R. Gonzalez, J.M. Garcia, C. Corbacho, M. Provencio, P. Espana and F. Bonilla, Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients, Br J Cancer 80 (1999), 1262-1264.
98. I.H. Wong, Y.M. Lo, J. Zhang, C.T. Liew, M.H. Ng, N. Wong, P.B. Lai, W.Y. Lau, N.M. Hjelm and P.J. Johnson, Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients, Cancer Res 59 (1999), 71-73.
99. I.H. Wong, P.J. Johnson, P.B. Lai, W.Y. Lau and Y.M. Lo, Tumor-derived epigenetic changes in the plasma and serum of liver cancer patients. Implications for cancer detection and monitoring, Ann N Y Acad Sci 906 (2000), 102-105.
100. A.T. Chan, Y.M. Lo, B. Zee, L.Y. Chan, B.B. Ma, S.F. Leung, F. Mo, M. Lai, S. Ho, D.P. Huang and P.J. Johnson, Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma, J Natl Cancer Inst 94 (2002), 1614-1619.
101. S.F. Leung, A.T. Chan, B. Zee, B. Ma, L.Y. Chan, P.J. Johnson and Y.M. Lo, Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type, Cancer 98 (2003), 288-291.
102. J.C. Lin, W.Y. Wang, K.Y. Chen, Y.H. Wei, W.M. Liang, J.S. Jan and R.S. Jiang, Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma, N Engl J Med 350 (2004), 2461-2470.
103. Y.M. Lo, W.Y. Chan, E.K. Ng, L.Y. Chan, P.B. Lai, J.S. Tam and S.C. Chung, Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma, Clin Cancer Res 7 (2001), 1856-1859.
104. K.F. Hsu, S.C. Huang, J.R. Hsiao, Y.M. Cheng, S.P. Wang and C.Y. Chou, Clinical significance of serum human papillomavirus DNA in cervical carcinoma, Obstet Gynecol 102 (2003), 1344-1351.
105. K. Kuroi, C. Tanaka and M. Toi, Clinical significance of plasma nucleosome levels in cancer patients, Int J Oncol 19 (2001), 143-148.
106. C. Trejo-Becerril, E. Perez-Cardenas, H. Trevino-Cuevas, L. Taja-Chayeb, P. Garcia-Lopez, B. Segura-Pacheco, A. Chavez-Blanco, M. Lizano-Soberon, A. Gonzalez-Fierro, I. Mariscal, T. Wegman-Ostrosky and A. Duenas-Gonzalez, Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients, Int J Cancer 104 (2003), 663-668.
107. S. Holdenrieder, P. Stieber, H. Bodenmuller, M. Busch, G. Fertig, H. Furst, A. Schalhorn, N. Schmeller, M. Untch and D. Seidel, Nucleosomes in serum of patients with benign and malignant diseases, Int J Cancer 95 (2001), 114-120.
108. M. Fleischhacker, T. Beinert, M. Ermitsch, D. Seferi, K. Possinger, C. Engelmann and B. Jandrig, Detection of amplifiable messenger RNA in the serum of patients with lung cancer, Ann N Y Acad Sci 945 (2001), 179-188.
109. M.S. Kopreski, F.A. Benko and C.D. Gocke, Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum, Ann N Y Acad Sci 945 (2001), 172-178.
110. J.M. Silva, R. Rodriguez, J.M. Garcia, C. Munoz, J. Silva, G. Dominguez, M. Provencio, P. Espana and F. Bonilla, Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells, Gut 50 (2002), 530-534.
111. J.M. Silva, G. Dominguez, J. Silva, J.M. Garcia, A. Sanchez, O. Rodriguez, M. Provencio, P. Espana and F. Bonilla, Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics, Clin Cancer Res 7 (2001), 2821-2825.
112. D.S. Hoon, P. Bostick, C. Kuo, T. Okamoto, H.J. Wang, R. Elashoff and D.L. Morton, Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence, Cancer Res 60 (2000), 2253-2257.